Expression of PD-L1 and PD-L2 and Their Association with IFN-γ/STAT1/STAT3 Signaling in Human Clear Cell Renal Cell

Gábor Kónya1,2, Ali Shammas1,2, Erzsébet Szabó3,4

  • 1Department of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.

Insights

Programmed cell death protein-1 (PD-1) ligands PD-L1 and PD-L2 are upregulated in kidney cancer. Interferon-gamma and STAT1 signaling dynamically regulate these immune checkpoints, offering insights for personalized immunotherapy.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Programmed cell death protein-1 (PD-1) and its ligands (PD-L1, PD-L2) are key regulators of T-cell activity and tumor immune escape.
  • The precise relationship between these immune checkpoints and STAT signaling in clear cell renal cell carcinoma (ccRCC) requires further elucidation.

Purpose of the Study:

  • To investigate the expression of PD-1, PD-L1, PD-L2, STAT1, and STAT3 in ccRCC tissues.
  • To examine the impact of interferon-gamma (IFN-γ) on immune checkpoint molecule expression and STAT pathway activation in ccRCC cell lines.

Main Methods:

  • Analysis of mRNA levels of PD-1, PD-L1, PD-L2, STAT1, and STAT3 in 27 paired ccRCC and adjacent non-tumorous human kidney tissues using RT-qPCR.
  • Treatment of ccRCC cell lines (CAKI-2, A-498) with IFN-γ to assess time-dependent modulation of immune checkpoint molecules and STAT pathway activation.

Main Results:

  • PD-L1 and PD-L2 were significantly upregulated in ccRCC tissues compared to normal kidney tissue, with a potential grade-dependent increase.
  • IFN-γ treatment induced rapid upregulation of PD-L1 and PD-L2 in ccRCC cell lines, peaking at 72 hours.
  • STAT1, but not STAT3, showed dynamic induction following IFN-γ stimulation, correlating with PD-L1/PD-L2 upregulation, while STAT1/STAT3 expression lacked direct association with PD-L1/PD-L2 levels in cancer samples.

Conclusions:

  • PD-L1 and PD-L2 are frequently upregulated in ccRCC and are dynamically regulated by IFN-γ/STAT1-dependent signaling.
  • These findings enhance understanding of immune escape mechanisms in ccRCC.
  • Integrated profiling of PD-1 ligands and STAT signaling may guide personalized ccRCC immunotherapeutic strategies.

Related Concept Videos